News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
pre clinical lab tests to confirm pre clinical lab tests.
This is routine in pre clinical testing and hardly something to put out a pr UNLESS you are a STINKY PINKY trying to pump up your pathetic pps.
Koos is the classical OTC scam artist CEO.
His pathetic track record with his public companies should be a warning to others but there are always those that love to gamble on scam artist run OTC companies in the hope of making a quick buck.
$RGBP #Shortsqueeze. How huge is your short position?
$RGBP has news to talk about and it gets posted on the message board.
Not true. What is true? You are constantly spamming the board with fear, uncertainty and doubt for the short positions you manage.
spamming the board with the same press release day after day is a great strategy! Keep up the great work.
$RGBP Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. https://www.wsj.com/articles/goldman-small-cap-research-publishes-new-research-report-on-regen-biopharma-inc-fe695ae1?reflink=mw_share_twitter
And you know how much of that Regen will see in any type of revenue?
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
FN Media Group LLC
Thu, October 12, 2023 at 9:00 AM EDT
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, which are expected to offer lucrative opportunities for market expansion and flourishing opportunities. The rise in awareness and upsurge in approvals of new CAR T-cell therapies and promising advanced drugs present in pipelines are anticipated to offer remunerative opportunities for the expansion for the global CAR T-cell therapy market in the near future. Some of the benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery, and shortened treatment time. In addition, CAR T-cell therapy survives for a long time in the body, as they have the ability to recognize and target cancer cells even if the cancer relapses. According to a report released by Precedence Research, the global cell therapy market was valued at US$ 12 billion in 2022 and it is expected to hit US$ 83.78 billion by 2032, poised to grow at a CAGR of 21.50% during the forecast period 2023 to 2032. Further, an additional report by Allied Market Research stated the global car t-cell therapy market size was valued at $1.7 billion in 2021, and is projected to reach $6.1 billion by 2031. Active biotech and pharma companies in the markets this week include Amgen (NASDAQ:AMGN), Regen BioPharma, Inc. (OTCPK:RGBP), Gilead Sciences, Inc. (NASDAQ:GILD), GSK plc (NYSE:GSK), Incyte (NASDAQ:INCY).
Precedence Research added: “The growth of global cell therapy market is attributed to the rising incidents of chronic disorders and infections. In addition, the growing cases of diabetes are also boosting the market growth. As per the International Diabetes Federation Diabetes Altas, almost 573 million persons globally had diabetes in 2022, with the number anticipated to grow by 643 million by 2032 and 783 million by 2045. Moreover, the growing number of research studies and clinical trials are also boosting the growth of global cell therapy market. One of the key factors propelling the expansion of global cell therapy market is adoption of innovative and latest technologies. Furthermore, after the impact of COVID-19 pandemic, the market for cell therapy is growing at a rapid pace. With over 900 companies working on advanced therapeutics around the world and around 1,000 cell or gene therapy clinical studies now conducted, the cell therapy market might see a surge in number of approvals. According to industry experts, up to 60 new cell therapies could be developed in the next few years, curing around 350,000 patients in the U.S. alone.”
Regen BioPharma, Inc. Receives First Phase of Confirmatory Study - Regen BioPharma, Inc. (OTCPK:RGBP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders.
The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."
"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company. CONTINUED… Read this full press release and more news for RGBP at: https://regenbiopharmainc.com/company-news1/
Media Contact email: editor @
SOURCE Financialnewsmedia.com
OMG! LIKEOMG! ThIS iS HuGe NeWs! https://finance.yahoo.com/news/global-car-t-cell-therapy-130000592.html
Don't forget to let us know that Reject Bio's patents are worth billions and that Koos is a "business leader!"
$RGBP - LOW FLOAT -Security Details updated:
lol @ liking your own posts.
$RGBP Regen BioPharma, Inc. Receives First Phase of Confirmatory Study. https://marketwatch.com/press-release/regen-biopharma-inc-receives-first-phase-of-confirmatory-study-aa21fca5?mod=mw_quote_news_seemore $TRUL $TCNNF $AYR $AYRWF $CURA $CUR $CBDLLF $TLRY $CGC $HEXO $PPCB
"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company.
$RGBP CEO
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."
$RGBP Chief Scientific Consultant
Another
NEWS: FULL PRESS RELEASE: PR Newswire as Regen BioPharma, Inc. Receives First Phase of Confirmatory Study
Tue, October 10, 2023 at 8:00 AM EDT
In this article: RGBP, RGBPP
CAR-T Cells Created
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."
"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharma.com
Cision
Cision
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-receives-first-phase-of-confirmatory-study-301951457.html
SOURCE Regen BioPharma, Inc.
Goldman's credibility is about as solid as Koos' bowel movements after a night of tacos in Tijuana.
$RGBP Regen BioPharma May Not Be Underfollowed for Long
Goldman commented, "Regen BioPharma may be an underfollowed and undervalued preclinical player today, but major steps on the R&D front could serve as a near-term catalyst for its stock. A recent set of experiments led by a highly regarded CRO unearthed surprising results in a recent study which could lead to a series of game-changing future milestone events. Regen has now evolved from primarily a cancer therapy product approach to a firm that now features autoimmune therapy development as well."
Autoimmune Market is Huge; Chronic Nature Attracts Investor Attention
"The autoimmune therapeutic segment is massive and impacts millions of sufferers around the world," noted Goldman. "According to Future Market Insights, this segment is projected to grow from an estimated $71.5 billion in 2023 to $123.5 billion in 2033. Autoimmune disorders (ADs) are a family of more than 100 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of auto-antibodies, inflammatory and mediatory cells and resulting chronic inflammation. ADs affect up to 9% of the population and can represent considerable personal and public health burdens."
Inherent Competitive Advantages and History Versus its Peers
Goldman stated, "The Company has a deep IP portfolio centered around a key validated target and a diverse preclinical product pipeline, with a focus on immune-oncology and autoimmune diseases. Regen's next-gen technology platforms have led to multiple IND submissions and an IND approval. Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months."
Reasonable 6-12 Month Target Price, Future Upside Led by Milestones
"Our target price represents a market cap which we believe is fair and typical for a preclinical firm with deep IP, next-gen tech, multiple target therapy markets, and one with a potential product on a clinical trial path. We believe additional price gains can be achieved as new objectives are met in the coming quarters," Goldman concluded.
$RGBP Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months.
Our 6-12-month price target is $5.00. This target represents a $17.5 million market cap
|
Followers
|
1050
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118425
|
|
Created
|
09/03/14
|
Type
|
Free
|
| Moderators SmellMyFinger | |||
0.000x Ticker Symbol: RGBP
Barchart
All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html
| Date | Outsanding Shares | Reason for Issue |
|---|---|---|
| 12/31/21 | 4,564,002,832 | |
| 3/28/22 | 4,580,002,832 | Debt and Interest |
| 4/7/22 | 4,736,002,832 | Debt and Interest |
| 5/16/22 | 4,820,002,832 | Debt |
| 7/1/22 | 4,920,002,832 | Debt |
| 7/17/22 | 4,970,002,832 | Debt and Interest |
| 8/1/22 | 5,024,517,324 | Debt |
| 8/4/22 | 5,031,517,324 | EXPENSES |
AI
